Archive \ Volume.12 2021 Issue 4

An Overview on Dry Eye Disease Evaluation and Management Approach in Primary Health Care Centre

Aziz Jarman M. Alsubaie , Saad Omar Alsaab , Rayan Nasser Alshuaylan , Sultan Hammad M Alosimi , Hussain Mohammed Al-Hasani , Khaled Nasser Alqahtani , Abdulhadi Shabib S Alqahtani , Nourah Alsubaiei , Ehdaa Khalid Boudal , Hussam Atallah
Abstract

Dry eye disease (DED) was previously characterized as a tear film disease caused by tear deficit or extreme evaporation, caused injury to the inter-palpebral ocular surface and ocular discomfort. Due to ocular discomfort, difficulties completing everyday tasks, and depression, patients with moderate-to-severe DED may have a worse quality of life. DED is a rapidly developing health concern with an increasing global prevalence. Therefore, the physician needs to acquire adequate knowledge about this disease to provide the best management to the DED patients. A literature review of published works on dry eye disease, evaluation, risk factors, and management. Article selection was performed in the Pub Med database with the mentioned mesh chief points ((“dry eye disease"[Mesh]) AND (“management”[Mesh]) OR (“risk factors"[Mesh])). The physician faces significant difficulty when it comes to treating DED. The major goals of DED treatment are to enhance the ease of a patient’s life, as well as to restore the ophthalmic surface and tear film to their natural homeostatic condition. It is recommended for the physician to start the first step in managing DED with prevention. However, the core of DED therapy is the use of over-the-counter ocular lubricants to enhance humidity at the ocular surface. Additional medications and dietary supplementations have been suggested also in the literature.



How to cite:
Vancouver
Alsubaie A J M, Alsaab S O, Alshuaylan R N, Alosimi S H M, Al-Hasani H M, Alqahtani K N, et al. An Overview on Dry Eye Disease Evaluation and Management Approach in Primary Health Care Centre. Arch. Pharm. Pract. 2021;12(4):58-64. https://doi.org/10.51847/rpLau6xsCV
APA
Alsubaie, A. J. M., Alsaab, S. O., Alshuaylan, R. N., Alosimi, S. H. M., Al-Hasani, H. M., Alqahtani, K. N., & et al (2021). An Overview on Dry Eye Disease Evaluation and Management Approach in Primary Health Care Centre. Archives Of Pharmacy Practice, 12(4),58-64. https://doi.org/10.51847/rpLau6xsCV

Download Citation
References

1.        Lee BS, Kabat AG, Bacharach J, Karpecki P, Luchs J. Managing dry eye disease and facilitating realistic patient expectations: a review and appraisal of current therapies. Clin Ophthalmol (Auckland, NZ). 2020;14:119-26. doi:10.2147/opth.s228838.

2.        Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. The ocular surface. 2017;15(3):575-628. doi:10.1016/j.jtos.2017.05.006.

3.        Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, Viso E. Tfos dews ii epidemiology report. Ocul Surf. 2017;15(3):334-65. doi:10.1016/j.jtos.2017.05.003.

4.        Pinho Tavares FD, Fernandes RS, Bernardes TF, Bonfioli AA, Carneiro Soares EJ. Dry eye disease. Semin Ophthalmol. 2010;25(3):84-93. doi:10.3109/08820538.2010.488568.

5.        Lemp MA, Baudouin C, Baum J, Dogru M, Foulks GN, Kinoshita S, et al. The definition and classification of dry eye disease: Report of the definition and classification subcommittee of the International dry eye workshop. Ocular Surf. 2007;5(2):75-92. doi:10.1016/s1542-0124(12)70081-2.

6.        Aggarwal S, Galor A. What’s new in dry eye disease diagnosis? Current advances and challenges. F1000Research. 2018;7:1952. doi:10.12688/f1000research.16468.1.

7.        Blehm C, Vishnu S, Khattak A, Mitra S, Yee RW. Computer vision syndrome: a review. Surv Ophthalmol. 2005;50(3):253-62. doi:10.1016/j.survophthal.2005.02.008.

8.        McDonald M, Patel DA, Keith MS, Snedecor SJ. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review. Ocul Surf. 2016;14(2):144-67. doi:10.1016/j.jtos.2015.11.002.

9.        Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30(4):379-87. doi:10.1097/ico.0b013e3181f7f363.

10.      Kaštelan S, Tomić M, Salopek-Rabatić J, Novak B. Diagnostic procedures and management of dry eye. BioMed Res Int. 2013;2013:1-6.  doi:10.1155/2013/309723.

11.      Dhyani A, Kumar G. A New Vision To Eye: Novel Ocular Drug Delivery System. Pharmacophores. 2019;10(1):13-20.

12.      Janine AS. The epidemiology of dry eye disease: report of the epidemiological subcommittee of the international dry eye workshop. Ocul Surf. 2007;5(2):93-107. doi:10.1016/s1542-0124(12)70082-4.

13.      Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118(9):1264-8. doi:10.1001/archopht.118.9.1264.

14.      Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. Tfos dews ii pathophysiology report. Ocul Surf. 2017;15(3):438-510. doi:10.1016/j.jtos.2017.05.011.

15.      Rajagopalan K, Abetz L, Mertzanis P, Espindle D, Begley C, Chalmers R, et al. Comparing the Discriminative Validity of Two Generic and One Disease‐Specific Health‐Related Quality of Life Measures in a Sample of Patients with Dry Eye. Value Health. 2005;8(2):168-74. doi:10.1111/j.1524-4733.2005.03074.x.

16.      Sullivan DA, Sullivan BD, Evans JE, Schirra F, Yamagami H, Liu M, et al. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci. 2002;966(1):211-22. doi:10.1111/j.1749-6632.2002.tb04217.x.

17.      Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmology. 2017;124(11):S20-6. doi:10.1016/j.ophtha.2017.05.031.

18.      Belmonte C, Nichols JJ, Cox SM, Brock JA, Begley CG, Bereiter DA, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15(3):404-37. doi:10.1016/j.jtos.2017.05.002.

19.      Galor A, Covington D, Levitt AE, McManus KT, Seiden B, Felix ER, et al. Neuropathic ocular pain due to dry eye is associated with multiple comorbid chronic pain syndromes. J Pain. 2016;17(3):310-8. doi:10.1016/j.jpain.2015.10.019.

20.      Sivanesan E, Levitt RC, Sarantopoulos CD, Patin D, Galor A. Noninvasive electrical stimulation for the treatment of chronic ocular pain and photophobia. Neuromodulation. 2018;21(8):727-34. doi:10.1111/ner.12742.

21.      Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71. doi:10.3238/arztebl.2015.0071.

22.      Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1(3):107-26. doi:10.1016/s1542-0124(12)70139-8.

23.      Johnston PR, Rodriguez J, Lane KJ, Ousler G, Abelson MB. The interblink interval in normal and dry eye subjects. Clin Ophthalmol (Auckland, NZ). 2013;7:253. doi:10.2147/opth.s39104.

24.      Zhang M, Kim E, Akpek EK. Prevalence and predictors of Sjögren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. Br J Ophthalmol. 2012;96(12):1498-503. doi:10.1136/bjophthalmol-2012-301767.

25.      Lee SY, Tong L. Lipid-containing lubricants for dry eye: a systematic review. Optom Vis Sci. 2012;89(11):1654-61. doi:10.1097/opx.0b013e31826f32e0.

26.      Celebi AR, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study. Graefe's Arch Clin Exp Ophthalmol. 2014;252(4):619-26. doi:10.1007/s00417-014-2599-1.

27.      Jackson WB. Management of dysfunctional tear syndrome: a Canadian consensus. Can J Ophthalmol. 2009;44(4):385-94. doi:10.3129/i09-015.

28.      Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130(1):90-100. doi:10.1001/archophthalmol.2011.364.

29.      Verjee MA, Brissette AR, Starr CE. Dry Eye Disease: Early Recognition with Guidance on Management and Treatment for Primary Care Family Physicians. Ophthalmol Ther. 2020;9(4):877-88. doi:10.1007/s40123-020-00308-z.

30.      Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276-83. doi:10.1016/j.jtos.2017.05.008.

31.      Lee JH, Lee W, Yoon JH, Seok H, Roh J, Won JU. Relationship between symptoms of dry eye syndrome and occupational characteristics: the Korean National Health and Nutrition Examination Survey 2010–2012. BMC Ophthalmol. 2015;15(1):1-9. doi:10.1186/s12886-015-0147-3.

32.      Abelson MB, Ousler GW, Maffei C. Dry eye in 2008. Curr Opin Ophthalmol. 2009;20(4):282-6. doi:10.1097/icu.0b013e32832b7578.

33.      Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124(11):S4-13. doi:10.1016/j.ophtha.2017.07.010.

34.      Yoon KC, Heo H, Im SK, You IC, Kim YH, Park YG. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol. 2007;144(1):86-92. doi:10.1016/j.ajo.2007.03.016